Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Table of Contents | Next Article »
Circulation Research. 1990;66:883-890

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Urata, H.
Right arrow Articles by Husain, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Urata, H.
Right arrow Articles by Husain, A.

Circulation Research, Vol 66, 883-890, Copyright © 1990 by American Heart Association

ARTICLES

Angiotensin II-forming pathways in normal and failing human hearts

H Urata, B Healy, RW Stewart, FM Bumpus and A Husain
Department of Heart and Hypertension Research, Cleveland Clinic Foundation, OH 44195-5071.

Reduced preload and afterload to the heart are important effects of angiotensin converting enzyme (ACE) inhibitors in the treatment of congestive heart failure. However, since angiotensin II (Ang II) directly increases the strength of myocardial contraction, suppression of Ang II formation by ACE inhibitors could potentially reduce the beneficial effects of Ang II on the failing heart. To study how ACE inhibition suppresses cardiac Ang II formation in man, we characterized ACE-dependent and ACE-independent Ang II-forming pathways in eight normal and 24 failing human hearts obtained at cardiac transplantation. Ang II-forming activity in left ventricular (LV) membrane preparations was assessed by measuring the conversion of [125I]angiotensin I (Ang I) to [125I]Ang II. LV [125I]Ang II-forming activity in normal hearts (35.5 +/- 2.7 fmol/min/mg, n = 8) was not different from that in hearts from patients with ischemic cardiomyopathy (25.5 +/- 2.9 fmol/min/mg, n = 9) and was 48% lower (p less than 0.001) in hearts from patients with idiopathic cardiomyopathy (18.5 +/- 1.9 fmol/min/mg, n = 15).(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
 Eur Heart J SupplHome page
K. K. Teo
Clinical evidence from ONTARGET: proven cardio- and vascular protection
Eur. Heart J. Suppl., December 1, 2009; 11(suppl_F): F9 - F15.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
P. C. Cristovam, C. P. Arnoni, M. C. C. de Andrade, D. E. Casarini, L. G. Pereira, N. Schor, and M. A. Boim
ACE-Dependent and Chymase-Dependent Angiotensin II Generation in Normal and Glucose-Stimulated Human Mesangial Cells
Experimental Biology and Medicine, August 1, 2008; 233(8): 1035 - 1043.
[Abstract] [Full Text] [PDF]

Home page
 EuropaceHome page
A. Goette and U. Lendeckel
Electrophysiological effects of angiotensin II. Part I: signal transduction and basic electrophysiological mechanisms
Europace, February 1, 2008; 10(2): 238 - 241.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
Y. J. Oh, J. H. Lee, S. B. Nam, J. K. Shim, J. H. Song, and Y. L. Kwak
Effects of chronic angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor treatments on neurohormonal levels and haemodynamics during cardiopulmonary bypass
Br. J. Anaesth., December 1, 2006; 97(6): 792 - 798.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
M. Paul, A. Poyan Mehr, and R. Kreutz
Physiology of local Renin-Angiotensin systems.
Physiol Rev, July 1, 2006; 86(3): 747 - 803.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
S Kasama, T Toyama, T Hatori, H Sumino, H Kumakura, Y Takayama, S Ichikawa, T Suzuki, and M Kurabayashi
Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure
Heart, May 1, 2006; 92(5): 625 - 630.
[Abstract] [Full Text] [PDF]

Home page
 ANGIOLOGYHome page
T. Akbulut, H. Akgoz, S. U. Dayi, S. E. Celik, U. Gurkan, and G. Tayyareci
Evaluation of Enalapril+Losartan Treatment with Cardiopulmonary Exercise Test in Patients with Left Ventricular Dysfunction
Angiology, March 1, 2006; 57(2): 181 - 186.
[Abstract] [PDF]

Home page
 HeartHome page
S Enomoto, M Yoshiyama, T Omura, R Matsumoto, T Kusuyama, S Kim, Y Izumi, K Akioka, H Iwao, K Takeuchi, et al.
Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction
Heart, December 1, 2005; 91(12): 1595 - 1600.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
M Yoshiyama, Y Nakamura, T Omura, Y Izumi, R Matsumoto, S Oda, K Takeuchi, S Kim, H Iwao, and J Yoshikawa
Angiotensin converting enzyme inhibitor prevents left ventricular remodelling after myocardial infarction in angiotensin II type 1 receptor knockout mice
Heart, August 1, 2005; 91(8): 1080 - 1085.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. Kasama, T. Toyama, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi
Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction
J. Am. Coll. Cardiol., March 1, 2005; 45(5): 661 - 667.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
T. L Ripley
Valsartan in Chronic Heart Failure
Ann. Pharmacother., March 1, 2005; 39(3): 460 - 469.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. J.V. McMurray, M. A. Pfeffer, K. Swedberg, and V. J. Dzau
Which Inhibitor of the Renin-Angiotensin System Should Be Used in Chronic Heart Failure and Acute Myocardial Infarction?
Circulation, November 16, 2004; 110(20): 3281 - 3288.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
C. N. Gring and G. S. Francis
A hard look at angiotensin receptor blockers in heart failure
J. Am. Coll. Cardiol., November 2, 2004; 44(9): 1841 - 1846.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
A. Schafer, D. Fraccarollo, P. Tas, I. Schmidt, G. Ertl, and J. Bauersachs
Endothelial dysfunction in congestive heart failure: ACE inhibition vs. angiotensin II antagonism
Eur J Heart Fail, March 1, 2004; 6(2): 151 - 159.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
S. A Doggrell and J. C Wanstall
Vascular chymase: pathophysiological role and therapeutic potential of inhibition
Cardiovasc Res, March 1, 2004; 61(4): 653 - 662.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. L. Mann and A. Deswal
Angiotensin-Receptor Blockade in Acute Myocardial Infarction -- A Matter of Dose
N. Engl. J. Med., November 13, 2003; 349(20): 1963 - 1965.
[Full Text] [PDF]

Home page
 CirculationHome page
L. S. Zisman, G. E. Meixell, M. R. Bristow, and C. C. Canver
Angiotensin-(1-7) Formation in the Intact Human Heart: In Vivo Dependence on Angiotensin II as Substrate
Circulation, October 7, 2003; 108(14): 1679 - 1681.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
R. S. McKelvie, J.-L. Rouleau, M. White, R. Afzal, J. B. Young, A. P. Maggioni, P. Held, and S. Yusuf
Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure
Eur. Heart J., October 1, 2003; 24(19): 1727 - 1734.
[Abstract] [Full Text] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
B. I. Jugdutt and V. Menon
Upregulation of Angiotensin II Type 2 Receptor and Limitation of Myocardial Stunning by Angiotensin II Type 1 Receptor Blockers during Reperfused Myocardial Infarction in the Rat
Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2003; 8(3): 217 - 226.
[Abstract] [PDF]

Home page
 J Am Coll CardiolHome page
M. Domanski, J. Norman, B. Pitt, M. Haigney, S. Hanlon, and E. Peyster
Diuretic use, progressive heart failure, and death in patients in the studies of left ventricular dysfunction (SOLVD)
J. Am. Coll. Cardiol., August 20, 2003; 42(4): 705 - 708.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. Kasama, T. Toyama, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi
Addition of Valsartan to an Angiotensin-Converting Enzyme Inhibitor Improves Cardiac Sympathetic Nerve Activity and Left Ventricular Function in Patients with Congestive Heart Failure
J. Nucl. Med., June 1, 2003; 44(6): 884 - 890.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. O. Kokkonen, K. A. Lindstedt, and P. T. Kovanen
Role For Chymase in Heart Failure: Angiotensin II-Dependent or -Independent Mechanisms?
Circulation, May 27, 2003; 107(20): 2522 - 2524.
[Full Text] [PDF]

Home page
 CirculationHome page
T. Matsumoto, A. Wada, T. Tsutamoto, M. Ohnishi, T. Isono, and M. Kinoshita
Chymase Inhibition Prevents Cardiac Fibrosis and Improves Diastolic Dysfunction in the Progression of Heart Failure
Circulation, May 27, 2003; 107(20): 2555 - 2558.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
M.A. Pfeffer
The intersection between acute coronary syndrome and heart failure
Eur. Heart J. Suppl., April 1, 2003; 5(suppl_C): C19 - C23.
[Abstract] [PDF]

Home page
 Cardiovasc ResHome page
Y. Nakamura, M. Yoshiyama, T. Omura, K. Yoshida, Y. Izumi, K. Takeuchi, S. Kim, H. Iwao, and J. Yoshikawa
Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodeling in rat myocardial infarction
Cardiovasc Res, January 1, 2003; 57(1): 48 - 54.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
H. Tokuyama, K. Hayashi, H. Matsuda, E. Kubota, M. Honda, K. Okubo, I. Takamatsu, S. Tatematsu, Y. Ozawa, S. Wakino, et al.
Differential Regulation of Elevated Renal Angiotensin II in Chronic Renal Ischemia
Hypertension, July 1, 2002; 40(1): 34 - 40.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
C.-C. Wei, B. Tian, G. Perry, Q. C. Meng, Y.-F. Chen, S. Oparil, and L. J. Dell'Italia
Differential ANG II generation in plasma and tissue of mice with decreased expression of the ACE gene
Am J Physiol Heart Circ Physiol, June 1, 2002; 282(6): H2254 - H2258.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
A. Goette, U. Lendeckel, and H. U Klein
Signal transduction systems and atrial fibrillation
Cardiovasc Res, May 1, 2002; 54(2): 247 - 258.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
G. R. Ellis, A. K. Nightingale, D. J. Blackman, R. A. Anderson, C. Mumford, G. Timmins, D. Lang, S. K. Jackson, M. D. Penney, M. J. Lewis, et al.
Addition of candesartan to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress
Eur J Heart Fail, March 1, 2002; 4(2): 193 - 199.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
R. Ferrari, G. Guardigli, G. Cicchitelli, M. Valgimigli, E. Merli, O. Soukhomorskaia, and C. Ceconi
Angiotensin II overproduction: enemy of the vessel wall
Eur. Heart J. Suppl., February 1, 2002; 4(suppl_A): A26 - A30.
[Abstract] [PDF]

Home page
 J Am Coll CardiolHome page
B. M. Massie
Neurohormonal blockade in chronic heart failure: How much is enough? can there be too much?
J. Am. Coll. Cardiol., January 2, 2002; 39(1): 79 - 82.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
C.-M. Yu, G. L. Tipoe, K. Wing-Hon Lai, and C.-P. Lau
Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction
J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1207 - 1215.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
N. H. Andersen and C. E. Mogensen
Review: Inhibition of the renin-angiotensin system, with particular reference to dual blockade treatment
Journal of Renin-Angiotensin-Aldosterone System, September 1, 2001; 2(3): 146 - 152.
[PDF]

Home page
 CirculationHome page
J. L. Rouleau, G. Kapuku, S. Pelletier, H. Gosselin, A. Adam, C. Gagnon, C. Lambert, and S. Meloche
Cardioprotective Effects of Ramipril and Losartan in Right Ventricular Pressure Overload in the Rabbit: Importance of Kinins and Influence on Angiotensin II Type 1 Receptor Signaling Pathway
Circulation, August 21, 2001; 104(8): 939 - 944.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
V. Richard, S. Hurel-Merle, E. Scalbert, G. Ferry, F. Lallemand, J.-P. Bessou, and C. Thuillez
Functional Evidence for a Role of Vascular Chymase in the Production of Angiotensin II in Isolated Human Arteries
Circulation, August 14, 2001; 104(7): 750 - 752.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
G. G. Neri Serneri, M. Boddi, L. Poggesi, I. Simonetti, M. Coppo, M. L. Papa, G. F. Lisi, M. Maccherini, R. Becherini, A. Boncompagni, et al.
Activation of cardiac renin-angiotensin system in unstable angina
J. Am. Coll. Cardiol., July 1, 2001; 38(1): 49 - 55.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Y. Iwamoto, K. Song, S. Takai, M. Yamada, D. Jin, M. Sakaguchi, H. Ueda, Y. Katsuoka, and M. Miyazaki
Multiple Pathways of Angiotensin I Conversion and Their Functional Role in the Canine Penile Corpus Cavernosum
J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 43 - 48.
[Abstract] [Full Text]

Home page
 Nephrol Dial TransplantHome page
J. L. Wilkinson-Berka, N. J. Gibbs, M. E. Cooper, S. L. Skinner, and D. J. Kelly
Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat
Nephrol. Dial. Transplant., July 1, 2001; 16(7): 1343 - 1349.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. Mankad, T. A. d'Amato, N. Reichek, W. E. McGregor, J. Lin, D. Singh, W. J. Rogers, and C. M. Kramer
Combined Angiotensin II Receptor Antagonism and Angiotensin-Converting Enzyme Inhibition Further Attenuates Postinfarction Left Ventricular Remodeling
Circulation, June 12, 2001; 103(23): 2845 - 2850.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
H. Matsubara
Renin-Angiotensin System in Human Failing Hearts : Message From Nonmyocyte Cells to Myocytes
Circ. Res., May 11, 2001; 88(9): 861 - 863.
[Full Text] [PDF]

Home page
 Circ. Res.Home page
L. H. Opie and M. N. Sack
Enhanced Angiotensin II Activity in Heart Failure : Reevaluation of the Counterregulatory Hypothesis of Receptor Subtypes
Circ. Res., April 13, 2001; 88(7): 654 - 658.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. C. Petrie, N. Padmanabhan, J. E. McDonald, C. Hillier, J. M. C. Connell, and J. J. V. McMurray
Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease
J. Am. Coll. Cardiol., March 15, 2001; 37(4): 1056 - 1061.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
N. K Hollenberg, S. Y Osei, M C. Lansang, D. A Price, and N. D. Fisher
Salt intake and non-ACE pathways for intrarenal angiotensin II generation in man
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1): 14 - 18.
[Abstract] [PDF]

Home page
 Circ. Res.Home page
K. Kushiku, H. Yamada, K. Shibata, R. Tokunaga, T. Katsuragi, and T. Furukawa
Upregulation of Immunoreactive Angiotensin II Release and Angiotensinogen mRNA Expression by High-Frequency Preganglionic Stimulation at the Canine Cardiac Sympathetic Ganglia
Circ. Res., January 19, 2001; 88(1): 110 - 116.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. Kim, M. Yoshiyama, Y. Izumi, H. Kawano, M. Kimoto, Y. Zhan, and H. Iwao
Effects of Combination of ACE Inhibitor and Angiotensin Receptor Blocker on Cardiac Remodeling, Cardiac Function, and Survival in Rat Heart Failure
Circulation, January 2, 2001; 103(1): 148 - 154.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
A. Sigurdsson, S.V. Eriksson, C. Hall, T. Kahan, and K. Swedberg
Early neurohormonal effects of trandolapril in patients with left ventricular dysfunction and a recent acute myocardial infarction: a double-blind, randomized, placebo-controlled multicentre study
Eur J Heart Fail, January 1, 2001; 3(1): 69 - 78.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
A. Erman, G. Boner, and D. J van Dijk
Should the use of short acting angiotensin-converting enzyme inhibitors be abandoned?
Journal of Renin-Angiotensin-Aldosterone System, December 1, 2000; 1(4): 365 - 368.
[Abstract] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
H. Kawai, S. Y. Stevens, and C.-S. Liang
Renin-angiotensin system inhibition on noradrenergic nerve terminal function in pacing-induced heart failure
Am J Physiol Heart Circ Physiol, December 1, 2000; 279(6): H3012 - H3019.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
C. J. Clark, E. Davies, N. H. Anderson, R. Farmer, E. C. Friel, R. Fraser, and J. M. C. Connell
{{alpha}}-Adducin and Angiotensin I-Converting Enzyme Polymorphisms in Essential Hypertension
Hypertension, December 1, 2000; 36(6): 990 - 994.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C. Blais Jr., D. Fortin, J.-L. Rouleau, G. Molinaro, and A. Adam
Protective Effect of Omapatrilat, a Vasopeptidase Inhibitor, on the Metabolism of Bradykinin in Normal and Failing Human Hearts
J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 621 - 626.
[Abstract] [Full Text]

Home page
 HypertensionHome page
Y. Xu, A. S. Clanachan, and B. I. Jugdutt
Enhanced Expression of Angiotensin II Type 2 Receptor, Inositol 1,4,5-Trisphosphate Receptor, and Protein Kinase C{epsilon} During Cardioprotection Induced by Angiotensin II Type 2 Receptor Blockade
Hypertension, October 1, 2000; 36(4): 506 - 510.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
M. S Weinberg, A. J Weinberg, and D. H Zappe
Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors
Journal of Renin-Angiotensin-Aldosterone System, September 1, 2000; 1(3): 217 - 233.
[PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. Maruyama, E. Hatta, K. Yasuda, N. C. E. Smith, and R. Levi
Angiotensin-Converting Enzyme-Independent Angiotensin Formation in a Human Model of Myocardial Ischemia: Modulation of Norepinephrine Release by Angiotensin Type 1 and Angiotensin Type 2 Receptors
J. Pharmacol. Exp. Ther., July 1, 2000; 294(1): 248 - 254.
[Abstract] [Full Text]

Home page
 CirculationHome page
H. Nakashima, K. Kumagai, H. Urata, N. Gondo, M. Ideishi, and K. Arakawa
Angiotensin II Antagonist Prevents Electrical Remodeling in Atrial Fibrillation
Circulation, June 6, 2000; 101(22): 2612 - 2617.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
Yi Xu, V. Menon, and B. I Jugdutt
Cardioprotection after angiotensin II type 1 blockade involves angiotensin II type 2 receptor expression and activation of protein kinase C-{varepsilon} in acutely reperfused myocardial infarction in the dog: Effect of UP269-6 and losartan on AT1- and AT2-receptor expression and IP3 receptor and PKC{varepsilon} proteins
Journal of Renin-Angiotensin-Aldosterone System, June 1, 2000; 1(2): 184 - 195.
[Abstract] [PDF]

Home page
 Journal of Renin-Angiotensin-Aldosterone SystemHome page
H. Urata
Pathological involvement of chymase-dependent angiotensin II formation in the development of cardiovascular disease
Journal of Renin-Angiotensin-Aldosterone System, June 1, 2000; 1(2_suppl): S35 - S37.
[Abstract] [PDF]

Home page
 CirculationHome page
A. Saino, G. Pomidossi, R. Perondi, A. Morganti, L. Turolo, and G. Mancia
Modulation of Sympathetic Coronary Vasoconstriction by Cardiac Renin-Angiotensin System in Human Coronary Heart Disease
Circulation, May 16, 2000; 101(19): 2277 - 2283.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
J. J. Saris, M. A. van Dijk, I. Kroon, M. A. D. H. Schalekamp, and A. H. J. Danser
Functional Importance of Angiotensin-Converting Enzyme-Dependent In Situ Angiotensin II Generation in the Human Forearm
Hypertension, March 1, 2000; 35(3): 764 - 768.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
E. Mervaala, D. N. Muller, F. Schmidt, J.-K. Park, V. Gross, M. Bader, V. Breu, D. Ganten, H. Haller, and F. C. Luft
Blood Pressure-Independent Effects in Rats With Human Renin and Angiotensinogen Genes
Hypertension, February 1, 2000; 35(2): 587 - 594.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
D.J. van Veldhuisen and A.A. Voors
Blockade of the renin angiotensin system in heart failure: the potential place of angiotensin II receptor blockers
Eur. Heart J., January 1, 2000; 21(1): 14 - 16.
[PDF]

Home page
 Eur Heart JHome page
E Roig, F Perez-Villa, M Morales, W Jimenez, J Orus, M Heras, and G Sanz
Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure
Eur. Heart J., January 1, 2000; 21(1): 53 - 57.
[Abstract] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
D. W. O'Brien, Y. Xu, V. Menon, and B. I. Jugdutt
Efficacy of Pretreatment With the Angiotensin II Type 1 Receptor Blocker UP269-6 and Losartan in the Dog: Effect on Hemodynamics and Ischemia-Reperfusion
Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(2): 129 - 137.
[Abstract] [PDF]

Home page
 HypertensionHome page
J. R. Gonzalez-Juanatey, A. P. Reino, J. M. Garcia-Acuna, C. Gonzalez-Juanatey, L. Valdes, and J. Cabezas-Cerrato
Step-Down of Enalapril Treatment for Arterial Hypertension
Hypertension, December 1, 1999; 34(6): 1287 - 1292.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. H. McElmurray III, R. Mukherjee, R. B. New, A. C. Sampson, M. K. King, J. W. Hendrick, A. Goldberg, T. J. Peterson, H. Hallak, M. R. Zile, et al.
Angiotensin-Converting Enzyme and Matrix Metalloproteinase Inhibition with Developing Heart Failure: Comparative Effects on Left Ventricular Function and Geometry
J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 799 - 811.
[Abstract] [Full Text]

Home page
 Cardiovasc ResHome page
A.H.J. Danser, J. J Saris, M. P Schuijt, and J. P van Kats
Is there a local renin--angiotensin system in the heart?
Cardiovasc Res, November 1, 1999; 44(2): 252 - 265.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
A. MaassenVanDenBrink, R. de Vries, P. R. Saxena, M. A.D.H. Schalekamp, and A.H.J. Danser
Vasoconstriction by in situ formed angiotensin II: role of ACE and chymase
Cardiovasc Res, November 1, 1999; 44(2): 407 - 415.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
H. HAMADA, M. TERAI, H. KIMURA, K. HIRANO, S. OANA, and H. NIIMI
Increased Expression of Mast Cell Chymase in the Lungs of Patients with Congenital Heart Disease Associated with Early Pulmonary Vascular Disease
Am. J. Respir. Crit. Care Med., October 1, 1999; 160(4): 1303 - 1308.
[Abstract] [Full Text]

Home page
 CirculationHome page
B. H. Greenberg
Role of Angiotensin Receptor Blockers in Heart Failure : Not Yet RESOLVD
Circulation, September 7, 1999; 100(10): 1032 - 1034.
[Full Text] [PDF]

Home page
 Cardiovasc ResHome page
K. C Wollert and H. Drexler
The renin-angiotensin system and experimental heart failure
Cardiovasc Res, September 1, 1999; 43(4): 838 - 849.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
D. J. Campbell, A.-M. Duncan, and A. Kladis
Angiotensin-Converting Enzyme Inhibition Modifies Angiotensin but Not Kinin Peptide Levels in Human Atrial Tissue
Hypertension, August 1, 1999; 34(2): 171 - 175.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
C. A.M van Kesteren, J. J Saris, D. H.W Dekkers, J. M.J Lamers, P. R Saxena, M. A.D.H Schalekamp, and A.H.J. Danser
Cultured neonatal rat cardiac myocytes and fibroblasts do not synthesize renin or angiotensinogen: evidence for stretch-induced cardiomyocyte hypertrophy independent of angiotensin II
Cardiovasc Res, July 1, 1999; 43(1): 148 - 156.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
N. Padmanabhan, A. G. Jardine, J. C. McGrath, and J. M. C. Connell
Angiotensin-Converting Enzyme–Independent Contraction to Angiotensin I in Human Resistance Arteries
Circulation, June 8, 1999; 99(22): 2914 - 2920.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
D. Inui, M. Yoshizumi, N. Okishima, H. Houchi, K. Tsuchiya, H. Kido, and T. Tamaki
Mechanism of endothelin-1-(1---31)-induced calcium signaling in human coronary artery smooth muscle cells
Am J Physiol Endocrinol Metab, June 1, 1999; 276(6): E1067 - E1072.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
S. Yasuda, Y. Goto, H. Sumida, T. Noguchi, T. Baba, S. Miyazaki, and H. Nonogi
Angiotensin-Converting Enzyme Inhibition Restores Hepatocyte Growth Factor Production in Patients With Congestive Heart Failure
Hypertension, June 1, 1999; 33(6): 1374 - 1378.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
M. Ihara, H. Urata, A. Kinoshita, J. Suzumiya, M. Sasaguri, M. Kikuchi, M. Ideishi, and K. Arakawa
Increased Chymase-Dependent Angiotensin II Formation in Human Atherosclerotic Aorta
Hypertension, June 1, 1999; 33(6): 1399 - 1405.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
L. Baruch, I. Anand, I. S. Cohen, S. Ziesche, D. Judd, and J. N. Cohn
Augmented Short- and Long-Term Hemodynamic and Hormonal Effects of an Angiotensin Receptor Blocker Added to Angiotensin Converting Enzyme Inhibitor Therapy in Patients With Heart Failure
Circulation, May 25, 1999; 99(20): 2658 - 2664.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
C.-C. Wei, Q. C. Meng, R. Palmer, G. R. Hageman, J. Durand, W. E. Bradley, D. M. Farrell, G. H. Hankes, S. Oparil, and L. J. Dell'Italia
Evidence for Angiotensin-Converting Enzyme– and Chymase-Mediated Angiotensin II Formation in the Interstitial Fluid Space of the Dog Heart In Vivo
Circulation, May 18, 1999; 99(19): 2583 - 2589.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. O. Kokkonen, A. Kuoppala, J. Saarinen, K. A. Lindstedt, and P. T. Kovanen
Kallidin- and Bradykinin-Degrading Pathways in Human Heart : Degradation of Kallidin by Aminopeptidase M–Like Activity and Bradykinin by Neutral Endopeptidase
Circulation, April 20, 1999; 99(15): 1984 - 1990.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
C. Richer, P. Fornes, C. Cazaubon, V. Domergue, D. Nisato, and J.-F. Giudicelli
Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats
Cardiovasc Res, January 1, 1999; 41(1): 100 - 108.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
L. S. Zisman, K. Asano, D. L. Dutcher, A. Ferdensi, A. D. Robertson, M. Jenkin, E. W. Bush, T. Bohlmeyer, M. B. Perryman, and M. R. Bristow
Differential Regulation of Cardiac Angiotensin Converting Enzyme Binding Sites and AT1 Receptor Density in the Failing Human Heart
Circulation, October 27, 1998; 98(17): 1735 - 1741.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
H. Nishimura, H. Buikema, O. Baltatu, D. Ganten, and H. Urata
Functional evidence for alternative ANG II-forming pathways in hamster cardiovascular system
Am J Physiol Heart Circ Physiol, October 1, 1998; 275(4): H1307 - H1312.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
N. K. Hollenberg, N. D. L. Fisher, and D. A. Price
Pathways for Angiotensin II Generation in Intact Human Tissue : Evidence From Comparative Pharmacological Interruption of the Renin System
Hypertension, September 1, 1998; 32(3): 387 - 392.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
M. Akasu, H. Urata, A. Kinoshita, M. Sasaguri, M. Ideishi, and K. Arakawa
Differences in Tissue Angiotensin II–Forming Pathways by Species and Organs In Vitro
Hypertension, September 1, 1998; 32(3): 514 - 520.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
P. H. Lane, L. D. Tyler, and P. G. Schmitz
Chronic administration of furosemide augments renal weight and glomerular capillary pressure in normal rats
Am J Physiol Renal Physiol, August 1, 1998; 275(2): F230 - F234.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
Y.-T. Shen, R.T. Wiedmann, B.D. Greenland, J.J. Lynch, and W. Grossman
Combined effects of angiotensin converting enzyme inhibition and angiotensin II receptor antagonism in conscious pigs with congestive heart failure
Cardiovasc Res, August 1, 1998; 39(2): 413 - 422.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. P. van Kats, A. H. J. Danser, J. R. van Meegen, L. M. A. Sassen, P. D. Verdouw, and M. A. D. H. Schalekamp
Angiotensin Production by the Heart : A Quantitative Study in Pigs With the Use of Radiolabeled Angiotensin Infusions
Circulation, July 7, 1998; 98(1): 73 - 81.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
R.S. Krombach, M. J Clair, J. W Hendrick, W. V Houck, J. L Zellner, S. B Kribbs, S. Whitebread, R. Mukherjee, M. de Gasparo, and F. G Spinale
Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns
Cardiovasc Res, June 1, 1998; 38(3): 631 - 645.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
N. J. Brown and D. E. Vaughan
Angiotensin-Converting Enzyme Inhibitors
Circulation, April 14, 1998; 97(14): 1411 - 1420.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. A. Owen and E. J. Campbell
Angiotensin II Generation at the Cell Surface of Activated Neutrophils: Novel Cathepsin G-Mediated Catalytic Activity That Is Resistant to Inhibition
J. Immunol., February 1, 1998; 160(3): 1436 - 1443.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
C. Richer, P. Bruneval, J. Menard, and J.-F. Giudicelli
Additive Effects of Enalapril and Losartan in (mREN-2)27 Transgenic Rats
Hypertension, February 1, 1998; 31(2): 692 - 698.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
D. N. Muller, W. Fischli, J.-P. Clozel, K. F. Hilgers, J. Bohlender, J. Menard, A. Busjahn, D. Ganten, and F. C. Luft
Local Angiotensin II Generation in the Rat Heart : Role of Renin Uptake
Circ. Res., January 23, 1998; 82(1): 13 - 20.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
R. H. Ritchie, J. D. Marsh, W. D. Lancaster, C. A. Diglio, and R. J. Schiebinger
Bradykinin Blocks Angiotensin II-Induced Hypertrophy in the Presence of Endothelial Cells
Hypertension, January 1, 1998; 31(1): 39 - 44.
[Abstract] [Full Text]

Home page
 CirculationHome page
W. W. Brooks, O. H. L. Bing, K. G. Robinson, M. T. Slawsky, D. M. Chaletsky, and C. H. Conrad
Effect of Angiotensin-Converting Enzyme Inhibition on Myocardial Fibrosis and Function in Hypertrophied and Failing Myocardium From the Spontaneously Hypertensive Rat
Circulation, December 2, 1997; 96(11): 4002 - 4010.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
F. G. Spinale, H. H. Holzgrefe, R. Mukherjee, M. L. Webb, R. B. Hird, M. J. Cavallo, J. R. Powell, and W. H. Koster
Angiotensin-Converting Enzyme Inhibition and Angiotensin II Subtype-1 Receptor Blockade during the Progression of Left Ventricular Dysfunction: Differential Effects on Myocyte Contractile Processes
J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1082 - 1094.
[Abstract] [Full Text]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
E. A. Garrison, H. C. Champion, and P. J. Kadowitz
[Pro11,D-Ala12]angiotensin I has rapid onset vasoconstrictor activity in the cat
Am J Physiol Endocrinol Metab, December 1, 1997; 273(6): E1059 - E1064.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. Menard, D. J. Campbell, M. Azizi, and M.-F. Gonzales
Synergistic Effects of ACE Inhibition and Ang II Antagonism on Blood Pressure, Cardiac Weight, and Renin in Spontaneously Hypertensive Rats
Circulation, November 4, 1997; 96(9): 3072 - 3078.
[Abstract] [Full Text]

Home page
 CirculationHome page
F. G. Spinale, M. de Gasparo, S. Whitebread, L. Hebbar, M. J. Clair, D. M. Melton, R. S. Krombach, R. Mukherjee, J. P. Iannini, and S.-J. O
Modulation of the Renin-Angiotensin Pathway Through Enzyme Inhibition and Specific Receptor Blockade in Pacing-Induced Heart Failure : I. Effects on Left Ventricular Performance and Neurohormonal Systems
Circulation, October 7, 1997; 96(7): 2385 - 2396.
[Abstract] [Full Text]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
E. Balcells, Q. C. Meng, W. H. Johnson Jr., S. Oparil, and L. J. Dell'Italia
Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations
Am J Physiol Heart Circ Physiol, October 1, 1997; 273(4): H1769 - H1774.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. E. Donckier, P.-E. Massart, D. Hodeige, H. Van Mechelen, J.-P. Clozel, O. Laloux, J.-M. Ketelslegers, A. A. Charlier, and G. R. Heyndrickx
Additional Hypotensive Effect of Endothelin-1 Receptor Antagonism in Hypertensive Dogs Under Angiotensin-Converting Enzyme Inhibition
Circulation, August 19, 1997; 96(4): 1250 - 1256.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
Y. Sawada, M. Suda, H. Yokoyama, T. Kanda, T. Sakamaki, S. Tanaka, R. Nagai, S. Abe, and T. Takeuchi
Stretch-induced Hypertrophic Growth of Cardiocytes and Processing of Brain-type Natriuretic Peptide Are Controlled by Proprotein-processing Endoprotease Furin
J. Biol. Chem., August 15, 1997; 272(33): 20545 - 20554.
[Abstract] [Full Text] [PDF]


Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 1990 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.